Definitive Healthcare Corp (DH)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $140.38M
Last updated: Nov 17, 2026 at 11:02 AM ET
Definitive Healthcare Corp (DH) Stock Forecast
Analysts expect Definitive Healthcare (DH) to earn $0.22 per share in the fiscal year ending Dec 31, 2026, on revenue of $221.38M. Of 6 analysts, 1 rates the stock Buy or Strong Buy, 4 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 3.17, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 17% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 1 | 16.7% |
| Hold | 4 | 66.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 16.7% |
- Consensus
- Hold
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 13.6% and revenue estimates fall 0.4%.
- Fiscal year ending Dec 31, 2026
- $0.22
- EPS consensus, revenue $221.38M
- Fiscal year ending Dec 31, 2027
- $0.19
- EPS consensus, revenue $220.52M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.22 | $0.22 to $0.22 | 1 | $221.38M | $221.09M to $221.67M | 4 |
| Dec 31, 2027 | $0.19 | $0.16 to $0.21 | 6 | $220.52M | $210.65M to $230.00M | 6 |
Quarterly Estimates
The EPS consensus rises from $0.04 for the quarter ending Dec 31, 2026 to $0.05 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.04 | $0.03 to $0.06 | 9 | $57.23M | $54.21M to $58.70M | 7 |
| Mar 31, 2027 | $0.05 | $0.04 to $0.05 | 5 | $56.08M | $53.74M to $58.17M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 6 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 4 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 2 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 15.8% from $0.19.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.22 | $0.20 | $0.19 | $0.19 | $0.19 | +14.6% |
| Fiscal year ending Dec 31, 2027 | $0.19 | $0.19 | $0.19 | $0.19 | $0.19 | -0.5% |
| Quarter ending Mar 31, 2027 | $0.05 | $0.05 | $0.05 | $0.05 | $0.05 | +1.5% |
Frequently Asked Questions About DH
What is the DH stock forecast?
Consensus analyst estimates put Definitive Healthcare's EPS at $0.22 for the fiscal year ending Dec 31, 2026, on revenue of $221.38M. The consensus rating from 6 analysts is Hold.
How do analysts rate DH stock?
Of 6 analysts covering Definitive Healthcare, 0 rate it Strong Buy, 1 Buy, 4 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from DH next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.22, with estimates from $0.22 to $0.22 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.19, with estimates from $0.16 to $0.21 from 6 analysts.
What revenue do analysts expect from Definitive Healthcare next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $221.38M, with estimates from $221.09M to $221.67M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $220.52M, with estimates from $210.65M to $230.00M.
How many analysts cover DH?
6 analysts rate Definitive Healthcare stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
DH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts